ClinicalTrials.gg
RecruitingNCT07849465Updated Sep 30, 2026

Hyperbaric Oxygen Therapy for Veterans With TBI and PCS: A Biomarker Study

A Phase 2 interventional study of Hyperbaric Oxygen Therapy (HBOT) in Traumatic Brain Injury (TBI) Patients, Post Concussive Symptoms and PTSD, sponsored by Summit Hyperbarics and Wellness. Recruiting at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-30.

Primary conditionPost-Concussion SyndromeRegistry: Brain Injuries, TraumaticReclassifiedWhy we changed it
Registry
Brain Injuries, Traumatic — the first condition term the registry derived for this study.
ClinicalTrials.gg
Post-Concussion Syndrome
Why
  1. The study's listed conditions name Post-Concussion Syndrome, a narrower term within Brain Injuries, Traumatic.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Summit Hyperbarics and Wellness · Phase 2, Interventional, and Treatment

Updated Sep 30, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
34
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 77 studies in Post-Concussion Syndrome with a site in United States — 15 open to participants now, 20 under way, 1 of them phase 3. Post-Concussion Syndrome · United States.

Planned enrollment
35th of 61
34 · median 40
Started
2026
with 6 others
Phase 2
14 of 77
5 open now
Primary completion
2027-10
later than 14 of 19 live
Registered
75th of 77
by date
Lead sponsor
4 of 77
Summit Hyperbarics and Wellness

Among the 77 studies in Post-Concussion Syndrome with a site in United States, this one is the 35th largest by planned enrollment of the 61 interventional ones that give a count, is one of 7 that started in 2026, is one of 14 in phase 2, reaches primary completion later than 14 of the 19 other live ones, and was the 75th registered.

Post-Concussion Syndrome

140 studies on the registry are indexed under Post-Concussion Syndrome; 33 are open to participants now.

Browse Post-Concussion Syndrome studies →

Open to participants now

15 of the 77 studies in Post-Concussion Syndrome with a site in United States are open now. Recruiting first, the newest first:

9 more — sign in →

All 15 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 24 Post-Concussion Syndrome studies recruiting now, 3 (13%) set no upper age limit and 20 (83%) stop at 75 or younger; 2 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 77 studies in Post-Concussion Syndrome with a site in United States, or all of them as a file.
02

Study summary

The goal of this study is to examine changes in blood biomarkers following hyperbaric oxygen therapy (HBOT) in military veterans with traumatic brain injury and persistent post-concussive symptoms. The main questions it aims to answer are:

  1. Does HBOT produce measurable changes in inflammatory, neurotrophic, and neuronal injury biomarkers from baseline to completion of a 40-session treatment protocol in veterans with TBI and PCS?
  2. Does the presence of comorbid PTSD influence biomarker responses to HBOT among veterans with TBI and PCS?

Participants will:

Complete medical and behavioral health evaluations to determine eligibility. Provide blood samples before treatment and after the final session. Receive 40 HBOT sessions at 2.0 ATA, generally two sessions per day with at least four hours between sessions.

Approximately 34 veterans will participate. All participants will receive HBOT; there is no comparison group.

Read the detailed description

This prospective, single-group study will evaluate changes in blood biomarkers following hyperbaric oxygen therapy (HBOT) in approximately 34 military veterans with a history of traumatic brain injury (TBI) and persistent post-concussive symptoms (PCS). The primary objective is to assess changes from baseline to completion of treatment in biomarkers associated with inflammation (CRP, IL-1, IL-6, IL-10, and TNF-α), neurotrophic activity (BDNF), and neuronal injury (NfL, GFAP, BD-tau, and UCH-L1). An exploratory objective is to assess whether biomarker changes differ between participants with and without comorbid post-traumatic stress disorder (PTSD).

Before treatment, participants will undergo medical and behavioral health evaluations to determine their suitability for HBOT. Eligible participants will complete a baseline blood draw for biomarker analysis and standard laboratory testing. Demographic, military service, and relevant clinical information will also be collected.

All participants will receive 40 HBOT sessions in a multiplace chamber at 2.0 atmospheres absolute (ATA). During each session, participants will breathe 100% oxygen for two 30-minute periods separated by a 5-minute air break. Sessions will be scheduled twice daily, Monday through Friday, with at least four hours between sessions. Blood collection and standard laboratory testing will be repeated after the 40-session protocol.

The study will use a pretest-posttest design without randomization or a control group. Within-participant biomarker changes will be evaluated using paired statistical tests, with adjustments for multiple comparisons in the primary biomarker analyses. Comparisons by comorbid PTSD status and associations between biomarker changes and clinical outcomes will be exploratory. Because all participants receive HBOT, observed changes cannot be attributed to HBOT alone.

03

Conditions studied

  • Traumatic Brain Injury (TBI) Patients
  • Post Concussive Symptoms
  • PTSD

Keywords

  • Traumatic brain injury (TBI)
  • Post-concussive symptoms (PCS)
  • Post-traumatic stress disorder
  • Veterans
  • Hyperbaric Oxygen Therapy (HBOT)
  • Blood biomarkers
  • Neuroinflammation
  • Neuronal Injury
04

In context

Post-Concussion Syndrome Reclassified

140 studies on the registry are indexed under Post-Concussion Syndrome; 33 are open to participants now.

This study's planned enrollment of 34 is below the median of 52 across 113 interventional studies indexed under Post-Concussion Syndrome.

Browse Post-Concussion Syndrome studies →

Lead sponsor

Summit Hyperbarics and Wellness is the lead sponsor of 4 studies on the registry; 4 are open to participants now.

Compared within Post-Concussion Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Brain Injuries, Traumatic. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. At least 18 years of age.
  2. Veteran status
  3. Clinically diagnosed with a TBI by a qualified healthcare professional.
  4. Participants with comorbid post-traumatic stress disorder (PTSD), diagnosed according to , Fifth Edition (DSM-5) criteria by a qualified and trained professional, are eligible for enrollment but are not required for study participation.

4. The participant is willing and able to read, understand, and sign an . Additionally, the participant has clear consciousness and the ability to express self-feelings independently.

6. Completed psychological measurements (pre-study screening requirement) 7. Presence of cognitive and/or PCS symptoms resulting in impairment in occupational, social, and other important areas of functioning, as determined by clinical evaluation.

8. Sexually active female participants of and sexually active male participants with female partners of childbearing potential must agree to use an acceptable method of for the duration of the study and for 30 days following the final HBOT session.

9. Stability on any prescribed psychoactive medications and/or other chronic medical medications. Stability is defined as no significant changes in type of dosage within the previous 4-5 weeks, to minimize confounding effects on study outcomes and ensure participant safety.

Exclusion criteria

Exclusion Criteria:

  1. Untreated pneumothorax
  2. History of spontaneous pneumothorax
  3. Asymptomatic pulmonary lesions on chest x-ray
  4. Uncontrollable high fever (greater than 39C)
  5. History of chest or ear surgery
  6. Congenital spherocytosis
  7. Any anemia or blood disorder
  8. Any convulsive disorder
  9. History of optic neuritis or sudden blindness
  10. Middle ear infection
  11. Diabetes mellitus (insulin therapy)
  12. The participant is pregnant or lactating
  13. Nicotine use/substance use/addiction
  14. Acute Hypoglycemia
  15. Diagnosed (COPD) and Emphysema
  16. Presenting with symptoms of cough, congestion, vomiting, diarrhea, or open wounds.
  17. Active
  18. Current manic, delusional, or psychotic episodes
  19. Serious/current suicidal ideations
  20. Severe or unstable physical disorders or major cognitive deficits
  21. Inability to attend scheduled clinic visits or comply with study protocols.
  22. Treated with HBOT for any reason prior to study enrollment.
  23. Non-English speakers
  24. History of retinal repair, including laser photocoagulation or retinal detachment surgery.
  25. History of middle ear surgery, including tympanoplasty, mastoidectomy, or pressure equalization tube placement.
  26. Age greater than 75 years.
  27. Use of any of the following medications during the study period: Anti-metabolites (e.g., methotrexate, azathioprine); Chemotherapeutic agents (e.g., cyclophosphamide, cisplatin); Mafenide acetate e.g., Sulfamylon); Disulfiram (e.g, Antabuse); Peripheral vasodilators known to interact with oxygen exposure (e.g., nitroglycerin); and Antibacterial drugs with known HBOT interaction risks.
  28. Recent vaccination (≤ 1 week), or underlying inflammatory conditions
  29. Use of systemic or immunomodulatory therapies
  30. Active or recent infection requiring antibiotics.
  31. Significant renal or hepatic impairment.
  32. Regular participation in intense physical training or exercise programs (Defined as endurance events (e.g., triathlons, marathons, ultramarathons, Ironman-level training) or high-intensity interval training (HIIT) programs performed multiple times per week)
  33. Recent (within 4 weeks prior to baseline) or planned use of antioxidant supplements or high-dose vitamins (Examples include: Vitamin C (> 500 mg/day), Vitamin E (>200 IU/day), N-acetylcysteine (NAC) or other thiol-based antioxidants, Alpha-lipoic acid, high-dose multivitamins containing the above doses, or Omega-3 fatty acid concentrates taken specifically for antioxidant/anti-inflammatory purposes)
  34. Recent participation in other clinical trials that could affect biomarker levels.
  35. Untreated or severe sleep disorders
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
34 participants (estimated)

Study arms

  • Experimental
    Hyperbaric Oxygen Therapy (HBOT) - 40 Sessions

    Participants in this arm will receive 40 hyperbaric oxygen therapy (HBOT) sessions in a multiplace chamber at 2.0 atmospheres absolute (ATA). Each session will include two 30-minute periods of breathing 100% oxygen, separated by a 5-minute air break. Sessions will occur twice daily, Monday through Friday, with at least four hours between sessions.

    Drug: Hyperbaric Oxygen Therapy (HBOT)

Interventions

  • DrugHyperbaric Oxygen Therapy (HBOT)

    Hyperbaric Oxygen Therapy (HBOT): Participants will complete 40 sessions at 2.0 atmospheres absolute (ATA). Each session includes two 30-minute periods of breathing 100% oxygen, separated by a 5-minute air break. Sessions are generally scheduled twice daily with at least four hours between them.

07

What researchers measure

Primary outcomes

  1. Change in blood C-reactive protein (CRP) concentration

    Difference in CRP concentration between baseline and completion of 40 HBOT sessions.

    Time frame: Baseline and after completion of 40 HBOT sessions (approximately 4 weeks).

  2. Change in blood interleukin-1 (IL-1) concentration

    Difference in IL-1 concentration between baseline and completion of 40 HBOT sessions.

    Time frame: Baseline and after completion of 40 HBOT sessions (approximately 4 weeks).

  3. Change in blood interleukin-6 (IL-6) concentration

    Difference in IL-6 concentration between baseline and completion of 40 HBOT sessions.

    Time frame: Baseline and after completion of 40 HBOT sessions (approximately 4 weeks).

  4. Change in blood interleukin-10 (IL-10) concentration

    Difference in IL-10 concentration between baseline and completion of 40 HBOT sessions.

    Time frame: Baseline and after completion of 40 HBOT sessions (approximately 4 weeks).

  5. Change in blood tumor necrosis factor-alpha (TNF-α) concentration

    Difference in TNF-α concentration between baseline and completion of 40 HBOT sessions.

    Time frame: Baseline and after completion of 40 HBOT sessions (approximately 4 weeks).

  6. Change in blood brain-derived neurotrophic factor (BDNF) concentration

    Difference in BDNF concentration between baseline and completion of 40 HBOT sessions.

    Time frame: Baseline and after completion of 40 HBOT sessions (approximately 4 weeks).

  7. Change in blood neurofilament light chain (NfL) concentration

    Difference in NfL concentration between baseline and completion of 40 HBOT sessions.

    Time frame: Baseline and after completion of 40 HBOT sessions (approximately 4 weeks).

  8. Change in blood glial fibrillary acidic protein (GFAP) concentration

    Difference in GFAP concentration between baseline and completion of 40 HBOT sessions.

    Time frame: Baseline and after completion of 40 HBOT sessions (approximately 4 weeks)

  9. Change in blood brain-derived tau (BD-tau) concentration

    Difference in BD-tau concentration between baseline and completion of 40 HBOT sessions.

    Time frame: Baseline and after completion of 40 HBOT sessions (approximately 4 weeks).

  10. Change in blood ubiquitin C-terminal hydrolase L1 (UCH-L1) concentration

    Difference in UCH-L1 concentration between baseline and completion of 40 HBOT sessions.

    Time frame: Baseline and after completion of 40 HBOT sessions (approximately 4 weeks).

08

Study locations

1 of 1 sites recruiting
09

References and documents

Related links

Individual participant data

Plan to share: No — There is no current plan to share IPD with researchers outside the study team. Given the small study population and the combination of sensitive clinical and military service information collected, participant-level data sharing could increase the risk of re-identification. Study findings will be reported in aggregate.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Oct 2027, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2026
First posted
Sep 30, 2026
StartEst.
Oct 1, 2026
Primary completionEst.
Oct 1, 2027
CompletionEst.
Oct 1, 2027
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07849465
Lead sponsor
Summit Hyperbarics and Wellness
Responsible party
Steve Wyman (Medical Director, Summit Hyperbarics and Wellness) — Principal investigator
First posted
Sep 30, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
Oct 1, 2027 (estimated)
Completion
Oct 1, 2027 (estimated)
Last update
Sep 30, 2026

Study contacts

Troy Nickel, Ph.D.
Contact
tnickel@shwidaho.org
208-813-9541
Steve Wyman, MD
principal investigator · Summit Hyperbarics and Wellness

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion